Action KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués NewAmsterdam Pharma Company N.V. Deutsche Boerse AG

Actions

KH6

NL00150012L7

Temps réel estimé Tradegate
Autres places de cotation
 10:12:29 04/07/2024 		Varia. 5j. Varia. 1 janv.
18,6 EUR +3,91 % Graphique intraday de NewAmsterdam Pharma Company N.V. +0,57 % +79,59 %
11/06 NewAmsterdam Pharma obtient un autre brevet américain prolongeant la protection de la propriété intellectuelle de l'obicétrapib jusqu'en juillet 2043 MT
10/06 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NAMS
  4. Action KH6
  5. Actualités NewAmsterdam Pharma Company N.V.
  6. Communiqués